Reductions in the size of the mismatch negativity (MMN), an event-related potential component elicited in response to unexpected stimuli, are arguably the most robust neurophysiological findings in schizophrenia. Several studies have now demonstrated that 'true' human-like deviance detection mismatch responses (MMRs) can be generated in the rodent brain and therefore that animal models can be used to examine the neurobiology of schizophrenia-like MMR impairments and investigate the efficacy of new treatments in addressing underlying neurobiological mechanisms. Two broad categories of animal models have been examined for schizophrenia-like MMRs: models involving N-methyl- D-aspartate receptor hypofunction, and models involving an insult or e...
International audienceThis article aims to provide a theoretical framework to elucidate the neurophy...
AbstractCognitive impairment is an important predictor of functional outcome in patients with schizo...
The lack of translation from basic research into new medicines is a major challenge in CNS drug deve...
One of the most robust electrophysiological features of schizophrenia is reduced mismatch negativity...
Mismatch negativity deficits, and by extension deficits in early cortical auditory information proce...
Recent reviews and meta-analyses suggest that reducing the duration of untreated psychosis leads to ...
Schizophrenia is associated with impairments in pre-attentive change detection, as represented by re...
Evidence suggests that anomalous mismatch negativity (MMN) in schizophrenia is related to glutamater...
AbstractEvidence suggests that anomalous mismatch negativity (MMN) in schizophrenia is related to gl...
<div><p>Mismatch negativity (MMN) is a scalp-recorded electrical potential that occurs in humans in ...
The mismatch negativity (MMN) is thought to be an index of the automatic activation of a specialized...
The auditory mismatch negativity (MMN) has been proposed as a biomarker of NMDA receptor (NMDAR) dys...
Impairments in mismatch negativity (MMN) in schizophrenia are well-established; these findings have ...
Mismatch Negativity (MMN) is an N-methyl-d-aspartic acid (NMDA)-mediated, negative deflection in hum...
Schizophrenia is associated with impairments in pre-attentive change detection, as represented by re...
International audienceThis article aims to provide a theoretical framework to elucidate the neurophy...
AbstractCognitive impairment is an important predictor of functional outcome in patients with schizo...
The lack of translation from basic research into new medicines is a major challenge in CNS drug deve...
One of the most robust electrophysiological features of schizophrenia is reduced mismatch negativity...
Mismatch negativity deficits, and by extension deficits in early cortical auditory information proce...
Recent reviews and meta-analyses suggest that reducing the duration of untreated psychosis leads to ...
Schizophrenia is associated with impairments in pre-attentive change detection, as represented by re...
Evidence suggests that anomalous mismatch negativity (MMN) in schizophrenia is related to glutamater...
AbstractEvidence suggests that anomalous mismatch negativity (MMN) in schizophrenia is related to gl...
<div><p>Mismatch negativity (MMN) is a scalp-recorded electrical potential that occurs in humans in ...
The mismatch negativity (MMN) is thought to be an index of the automatic activation of a specialized...
The auditory mismatch negativity (MMN) has been proposed as a biomarker of NMDA receptor (NMDAR) dys...
Impairments in mismatch negativity (MMN) in schizophrenia are well-established; these findings have ...
Mismatch Negativity (MMN) is an N-methyl-d-aspartic acid (NMDA)-mediated, negative deflection in hum...
Schizophrenia is associated with impairments in pre-attentive change detection, as represented by re...
International audienceThis article aims to provide a theoretical framework to elucidate the neurophy...
AbstractCognitive impairment is an important predictor of functional outcome in patients with schizo...
The lack of translation from basic research into new medicines is a major challenge in CNS drug deve...